This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
by Zacks Equity Research
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
LGNDPositive Net Change ALLOPositive Net Change ATHAPositive Net Change IBRXPositive Net Change
biotechs medical vaccines
Yeti (YETI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
YETIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Splash Beverage Group, Inc. (SBEV)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SBEVPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy ImmunoGen (IMGN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IMGNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View
by Zacks Equity Research
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
NVAXPositive Net Change LGNDPositive Net Change ALLOPositive Net Change ATHAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Should You Buy Bellus Health (BLU) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
DaVita HealthCare (DVA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DVAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Orchard Therapeutics PLC Sponsored ADR (ORTX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ORTXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.
ZTSPositive Net Change RCUSPositive Net Change ALLOPositive Net Change
biotechnology earnings medical vaccines
Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.
MRKPositive Net Change MRNAPositive Net Change AMRNPositive Net Change CRSPPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.
AZNPositive Net Change JNJPositive Net Change NVOPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals vaccines
GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook
by Zacks Equity Research
Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.
AZNPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
SNYPositive Net Change AZNPositive Net Change NVOPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals vaccines
Should You Buy Consolidated Edison (ED) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.
GSKPositive Net Change AMRNPositive Net Change CRSPPositive Net Change
biotechs medical vaccines
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
by Sundeep Ganoria
To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals vaccines
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence
by Zacks Equity Research
Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.
MRKPositive Net Change MRNAPositive Net Change LGNDPositive Net Change LSTAPositive Net Change
biotechs medical pharmaceuticals vaccines
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
by Zacks Equity Research
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.
MRNAPositive Net Change CRSPPositive Net Change CERTPositive Net Change
biotechs medical messenger-rna vaccines
Should You Buy Lululemon (LULU) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LULUPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Endeavour Silver (EXK) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
EXKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
NVOPositive Net Change HUMPositive Net Change CHGCYPositive Net Change HZNPPositive Net Change CSLLYNegative Net Change
biotechnology cancer cell-therapy dividend-investing dividends gene-therapy hmo hospitals immuno-therapy insurance large-cap medical pharmaceuticals vaccines
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
by Zacks Equity Research
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
CRSPPositive Net Change VBIVPositive Net Change CERTPositive Net Change
biotechs medical vaccines
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
by Zacks Equity Research
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
CRSPPositive Net Change IFRXPositive Net Change KALAPositive Net Change KODPositive Net Change
biotechnology medical vaccines
Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.
NVSPositive Net Change TEVANegative Net Change EBSNegative Net Change CRSPPositive Net Change
biotechs medical vaccines
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
GSKPositive Net Change NVOPositive Net Change SCYXPositive Net Change JSPRNegative Net Change
biotechnology medical vaccines